Re: [NMusers] $PK ADVAN6

subtracted dose: one with EVID=2 to get A-value, and another with EVID=1 to get dose to compartment 4 Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 On 9/1/2010

Re: [NMusers] $PK ADVAN6

I do not think the code below is correct either for Robert's case or for enterohepatic recycling Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 On 9/1/2010

Re: [NMusers] $PK ADVAN6

to the A(1) at time=6.9 (previous event record) Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 On 9/1/2010 5:02 PM, Mark Sale - Next Level Solutions wrote

Re: FW: [NMusers] Block versus diagonal omega

=THETA^2 In theta-form, the problem has two identical solution THETA()=SQRT(OMEGA)andTHETA()= -SQRT(OMEGA) Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566

Re: [NMusers] Trial optimization across multiple endpoints

is exactly the problem in your particular case? Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 On 8/28/2010 8:55 PM, Corrigan, Brian (Clin Pharm) wrote: Folks

Re: [NMusers] Issue with Volume of Peripheral Comp

Ayyappa Most likely, this is a coding error, so it would help if you post the code of your model. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 On 8/16

Re: [NMusers] Issue with Volume of Peripheral Comp

Ayyappa Most likely, this is a coding error, so it would help if you post the code of your model. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 On 8/16

Re: [NMusers] Baseline as a covariate

could be shifted). I would try both versions to see the differences, and then use the one that is more convenient to use in the particular situation. Best regards, Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail

Re: [NMusers] Comaprison of two models

that may influence parent-to-metabolite transformation, you may want to spend time investigating the entire system rather than only active metabolite. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky

Re: [NMusers] distribution assumption of Eta in NONMEM

mentioned: the mean estimate of OMEGA(1) was 0.0827 does it mean that Nonmem-estimated OMEGA was close to 0.0827 or you refer to the variances of estimated ETAs? Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail

Re: [NMusers] distribution assumption of Eta in NONMEM

) as ETAunif=TRANS(ETAnorm). Therefore, the true model can be presented (again, exactly) as CL=POPCL*exp(TRANS(ETAnorm)) This model should be used for estimation and according to Mats, should provide you the lowest OF Leonid -- Leonid Gibiansky, Ph.D. President

Re: [NMusers] nm7 IMP method question

I've seen on a number of examples (of non-linear differential equations models) the IMP method diverge (by increasing the OF indefinitely, until it hits infinity). In those cases, IMPMAP was more successful. Leonid -- Leonid Gibiansky, Ph.D. President

Re: [NMusers] Weibull Absorption Simulation - Multiple Doses

to follow what is going on. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Freeman, Burgess wrote: Dear NMUsers, I recently modeled some single dose

Re: [NMusers] Parallel first order and Michaelis-Menten elimination

. $SIGMA 1 FIX ; ~ERR -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 chenyuh...@netzero.net wrote: Dear All, I am working with a Biologic and would like to have a PK

Re: [NMusers] Parallel first order and Michaelis-Menten elimination

conventional error model of personal choice (hopefully supported by the data and confirmed by the VPC). Best ! Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566

Re: [NMusers] scaling problem??

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Varsha Mehta wrote: Dear Group: I hope someone can help me with the following scaling problem. I have data on two groups that I would like

Re: [NMusers] Meta-analysis with Nonmem

effect on error (thus accounting for possible differences in study populations; Y=IPRED+SE*EXP(ETA(1))*EPS(1)), etc. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566

Re: [NMusers] Predict AUC based on trough concentrations

system in terms of differential equations and add AUC compartment $DES ... DADT(5)=A(2)/S2 Values of A(5) at any time is the AUC from time zero up to the current time Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web

Re: [NMusers] computational issues preventing COV

MATRIX=S Could you provide more details of the output ? Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 markus joerger wrote: dear NONMEM community

Re: [NMusers] computational issues preventing COV

Hi Markus, On a separate note, this does not look like a traditional definition of IWRES (=IRES/sqrt(variance)): W=LOG(F) IRES=DV-IPRE IWRES=IRES/W Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail

Re: [NMusers] Sequential PK PD

, respectively, and nonmem will interpret it correctly My guess is that you should set K0=0, and then everything will work as you intended (the PK model should be identical to the PK part of the PD model). Thanks Leonid -- Leonid Gibiansky, Ph.D. President

Re: [NMusers] $ERROR and LOGIT

discussed various approached to the problem that you are trying to solve. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 non...@optonline.net wrote: Leonid

Re: [NMusers] $ERROR and LOGIT

= prediction of VAS ... Z=DLOG((VPRED/10+THETA(10))/(1-VPRED/10+THETA(10))) Y= Z + ERR(1) -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 non...@optonline.net wrote

Re: [NMusers] Duration of Absorption Time From Depot (Gut) as Covariate

-Original Message- From: owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com] On Behalf Of Leonid Gibiansky Sent: Friday, 11 December, 2009 6:55 To: prhut...@pharmacy.wisc.edu Cc: NMUSERS@GLOBOMAXNM.COM Subject: Re: [NMusers] Duration of Absorption Time From Depot (Gut

Re: [NMusers] $ERROR and LOGIT

/default.asp?abstract=1463 Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 non...@optonline.net wrote: Hello, NONMEM has the following property related

Re: [NMusers] Duration of Absorption Time From Depot (Gut) as Covariate

expression for IVIVC (for example, time scaling) to insert the dose into the depot compartment (as input rate) Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301

[NMusers] R/S+ nlme ODE

of new subjects given population parameters and variance-covariance matrix. Is this possible? If yes, could you send me a sample code? Thanks! Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky

Re: [NMusers] R/S+ nlme ODE

(as in your code) but then estimate individual parameters for a specific subject, based on his data, rather than use random parameters consistent with the population model. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web

Re: [NMusers] Modeling biomarker data below the LOQ

equations) and stiff. Based on the the indirect-response model simulations considered in your paper, LOQ/2 substitution seems to provide reasonable results if Laplacian (and thus M2-M3-M4) cannot be used. Thanks Leonid -- Leonid Gibiansky, Ph.D. President

Re: [NMusers] Modeling biomarker data below the LOQ

your data? If you are not satisfied, could you describe the deficiencies if there are any; these can help to resolve them. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel

Re: [NMusers] The system cannot execute the specified program

Pavel, Do you have enough RAM? I had something similar once when I used large size nonmem 7 installation (I do not remember the exact message, but this part: The system cannot execute the specified program was there for sure). Leonid -- Leonid Gibiansky

Re: [NMusers] PD modelling problem - Emax at lower bound?

) Initial conditions should be something like (0,50,100);EMAX (0, 2, 100) ;E0 Let me know of you have problem with this code, it should work. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky

Re: [NMusers] VPC appropriateness in complex PK

distributions should always be similar to the observed distributions even if the model is correct. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Wang

Re: [NMusers] VPC appropriateness in complex PK

controlled trials) or with the drop-out models. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Dider Heine wrote: Dear NMusers: The Visual predictive check

Re: [NMusers] VPC appropriateness in complex PK

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Wang, Diane wrote: Leonid, Thank you for the explanation. I was writing the response but found your email stated it even better than what I

Re: [NMusers] What does convergence/covariance show?

is an appropriate term. You probably mean uncertain ? or unreliable (read: with large standard errors?). Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Mark

Re: [NMusers] What does convergence/covariance show?

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 michael.j.foss...@gsk.com wrote: Leonid, this is not necessarily true. You may have data that can't be used to directly add to the model

Re: [NMusers] What does convergence/covariance show?

it :) Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Nick Holford wrote: Mats, [This thread contains several quite different directions so I've decided

Re: [NMusers] What does convergence/covariance show?

for all of us, this is still art, not science; therefore, the time when everything will be done by the computers is not too close. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel

Re: [NMusers] What does convergence/covariance show?

and variability of not only primary parameters (such as theta, omega, etc), but also relations between derived parameters. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767

Re: [NMusers] Linear VS LTBS

variables): W1=SQRT(THETA(...)/IPRED**2+THETA(...)) Y = LOG(IPRED) + W1*EPS(1) $SIGMA 1 FIXED Why concentrations were on LOQ? Was it because BQLs were inserted as LOQ? Then this is not a good idea. Thanks Leonid -- Leonid Gibiansky, Ph.D. President

Re: [NMusers] Code to avoid flip-flop kinetics

estimates), and it is not important if they are far apart. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Jurgen Bulitta wrote: Dear Nick, Dear Paolo

Re: [NMusers] Code to avoid flip-flop kinetics

(relative to the y-axis) peaks, then flip flop is interfering with the model. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Paolo Denti wrote

Re: [NMusers] OMEGA-Block

variability, and this can be seen on VPC plots. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Grevel, Joachim wrote: Dear Hauke, thanks

Re: [NMusers] COND LAPLACE LIKELIHOOD

.1) Y=PR1 IF (DV.EQ.2) Y=PR2 IF (DV.EQ.3) Y=PR3 B2 and B3 should be positive -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 wangx...@umn.edu wrote: Hi Samer

Re: [NMusers] COND LAPLACE LIKELIHOOD

the model is sensitive to initial values. Try to guess B1, B2, B3 (or at least B1) based on the observed data. Try B1=-1, B2=1, B3=1, Also, try to add random effect to B1. -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail

Re: [NMusers] OMEGA-Block

with the simplest model (assuming other diagnostics do not tell you otherwise). Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Hauke Rühs wrote

Re: [NMusers] OMEGA-Block

I guess, you can safely remove ETA4 on VSS from the model Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Hauke Rühs wrote: Dear NMusers, thank you

Re: [NMusers] Problem with HESSIAN

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Brogren, Jacob wrote: Hi Leonid, I tried to change to ADVAN8/ADVAN9 and TOL=8. I get the same error message. By the way, Martin Brgstrand tiped me about (F

Re: [NMusers] estimating Ka from dataset combining rich sample study and sparse sampling study

You can try IF(RICH data) THEN KA=THETA(1)*EXP(ETA(1)) ELSE KA=THETA(1) ENDIF -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Ethan Wu wrote: Dear Juergen

Re: [NMusers] forrtl: error (73): floating divide by zero

I would try IF(W.LE.0.01) W = 1 Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 hoxu8...@mail.usyd.edu.au wrote: Dear Nonmem users, I have been

Re: [NMusers] Bootstrap analysis

probability of observing the value as extreme as the final-model parameter estimates based on the bootstrap distribution (using a percent of bootstrap estimates that are below or above the final-model. estimate). Thanks Leonid -- Leonid Gibiansky, Ph.D

Re: [NMusers] OMEGA BLOCK with mixture model?

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Mats Karlsson wrote: Hi Leonid, Pls see below. Mats Karlsson, PhD Professor of Pharmacometrics Dept of Pharmaceutical

Re: [NMusers] OMEGA BLOCK with mixture model?

arm)? Is it always stable (or at least as stable as BLOCK(2))? Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Mats Karlsson wrote: Hi Steve

Re: [NMusers] VPC with Mixture Model

model diagnostics) Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Mats Karlsson wrote: Dear Satyendra, Interesting question. I don’t think

Re: [NMusers] VPC, NPC or PPC?

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 SIMON Nicolas wrote: Hi All, We have a dataset with as many dosing (amount and length of infusion) as patients. Once the final model was defined, I

Re: [NMusers] var-cov matrix issue?

, this use of the inverse variance-covariance matrix is somewhat limited. -- -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Bachman, William wrote: As a clarification

Re: [NMusers] Theoretical questions about Beal's M2 method

. As to the 0 to 1 restriction, l(t) is the density, not probability. It should integrate to one but can be smaller or greater than 1 (any positive number). Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky

Re: [NMusers] simulation question

the files needed to run nonmem (in R, use setwd(NonmemDirName) to do it) Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Ethan Wu wrote: Dear users, I am trying

Re: [NMusers] Identifiablity of parent / metabolite PK with interconversion

. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Dong-Seok Yim wrote: Leonid, Thank you for your comprehensive comment. Once I raised this, I wish to ask

Re: [NMusers] Identifiablity of parent / metabolite PK with interconversion

are missing VS=V2, VA=V3 somewhere. Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Dong-Seok Yim wrote: Hi, colleagues, I am currently trying to model

Re: [NMusers] CrcL or Cr in pediatric model

function? The suggestion was to define the renal disease as categorical variable, and then correct CL, for example: TCL ~ THETA(1) (for healthy) TCL ~ THETA(2) (for patients with severe renal impairment) Thanks Leonid -- Leonid Gibiansky, Ph.D. President

Re: [NMusers] CrcL or Cr in pediatric model

: if categorical description does not show any renal impairment effect, it makes no sense to use more complicated models, and it makes sense to explain dependence of CL on CRCL by WT, AGE or other available covariates. Best Leonid -- Leonid Gibiansky, Ph.D

Re: [NMusers] CrcL or Cr in pediatric model

Jakob, The model that I mentioned is not additive; it is multiplicative: Parameter= MeanValue*Effect1(WT)*Effect2(RF) but the effect of RF is expressed as a linear function of RF Effect2(RF) = 1 + THETA()*RF Leonid -- Leonid Gibiansky, Ph.D. President

Re: [NMusers] Modelling intracellular and plasma data

DADT(1) = -K*A(1) ; plasma C1=A(1)/V1 DADT(2) = K2*A(1)-K23*A(2) ;transit(can be duplicated to increase delay) DADT(3) = K23*A(3)-K30*A(3) ; intracellular C3=A(3)/V3 Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web

Re: [NMusers] FO vs FOCE, sequential vs simultaneous

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Xiao, Alan wrote: Dear All, I know this is an old topic, too, but would like to see the statistics. When you have a dataset

[NMusers] unscientific poll

-pasted after the summary of replies. Part 3: CSV file with the original data is copy-pasted after the comments Part 4: R code that I used to summarize the results is provided Thanks to all who participated. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm

Re: [NMusers] Models that abort before convergence Addendum

/publication FINAL model that did not converge (YES/NO): 8. Define yourself as novice/intermediate/experienced Nonmem user: Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301

Re: [NMusers] target-mediate model: numerical difficulties

(within the dose/concentration range of your data) Leonid Gibiansky, Ekaterina Gibiansky,Tarundeep Kakkar, Peiming Ma, Approximations of the Target-Mediated Drug Disposition Model and Identifiability of Model Parameters, PAGE 17 (2008) Abstract 1269 [www.page-meeting.org/?abstract=1269] http

Re: [NMusers] NONMEM memory vs. run time

capabilities. I think the OS manages to put active problems to RAM and non-active ones to swap space so that overall performance is not affected, but I am not sure, hence the question. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web

[NMusers] NONMEM memory vs. run time

time. Is it better (in terms of the run time) to use standard sizes, or big is OK if you have enough RAM? Thanks! Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566

Re: [NMusers] Estimation of standard error

be omitted. Or you can use separate errors for each CMT: Y1=F+F*EPS(1) Y2=F+F*EPS(2) Y=R1*Y1+R2*Y2 -- S2= V2 should help to get SE. If not, try MATRIX=S on $COV line. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e

Re: [NMusers] Estimation of standard error

Huali Even if it gives a good fit, S2=V1 is still an error. You may try to assume that V2=V1, and then S2=V2=V1, it is fine, but in the current form, equations are incorrect Thanks Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web

Re: [NMusers] iNTRAVENOUS VS. INTRA-ARTERIAL SAMPLING

; then, the difference gradually declined. Apart from the times when the rate of concentration changes was very high (concentration changed significantly within 1-2 minutes) the difference between arterial and venous concentrations was negligible. Leonid -- Leonid Gibiansky

Re: [NMusers] Sparse (pediatric) and rich (adult) data

dependence of CL on WT (if any is noticeable) for very young kids could be attributed to maturation and explained by AGE covariate Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel

Re: [NMusers] Sparse (pediatric) and rich (adult) data

, it is not a substitute for the real data. Even with optimal design of the pediatric study (with the same 20 subjects, 3 optimal sample points) I bet you would gain by using adult data as well. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web

Re: [NMusers] Sparse (pediatric) and rich (adult) data

is optimal. I think one should use both datasets together (in the specific case that was described) and it looks like we are in agreement on this point. Regards, Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail

Re: [NMusers] Visual predictive check!

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 andreas lindauer wrote: Dear NMusers, I have a question regarding simulations for a VPC. When a combined residual error is used it happens

Re: [NMusers] Body weight distribution

/about/major/nhanes/nh3data.htm Data can be sampled from this collection, or if needed, described in a parametric way to sample from a derived distribution. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail

Re: [NMusers] NM VI and NMV gave different results

output (error messages if any) Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Jian Xu wrote: Dear all, I did a Pop PK a year ago in NM V, and got a stable model

Re: [NMusers] IIV on %CV-Scale - Standard Error (SE)

Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Ribbing, Jakob wrote: Hi all, I think that Paul stumbled on a rather important issue. The SE of the residual

Re: [NMusers] Combined residual model and IWRES.

*THETA(3)+THETA(4)) Y=F*(1+SQRT(THETA(3))*ERR(1))+SQRT(THETA(4))*ERR(2). also, if you take the square of SE% in thetas, you will see that it nearly matches SE% for SIGMAs, as it should Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web

Re: [NMusers] Multiple amniotic fluid samples

per embryon, it is unlikely that you can distinguish between intra and inter subject variability, so I would put everything to noise (sigma). Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky

Re: [NMusers] Cmax, Tmax, and Time and AUC above threshold such as MIC

) $TABLE ID TIME CMAX TMAX CC2 CC7 CC8 The last record of each patient should provide desired values. Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Paul

Re: [NMusers] help with modelling of categorical response data

-- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 - $PRED CE=PROP ; define exposure: concentration, AUC or anything else ;PD EMAX=THETA(1)*EXP

Re: [NMusers] Reporting Modeling Results

statements. Best regards, Jeroen J. Elassaiss-Schaap Scientist PK/PD Organon NV PO Box 20, 5340 BH Oss, Netherlands Phone: + 31 412 66 9320 Fax: + 31 412 66 2506 e-mail: [EMAIL PROTECTED] -Original Message- From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED] On Behalf Of Leonid Gibiansky

Re: [NMusers] different COMRES statements

to be computed and replaced by a particular number, X is the number of elements required for implementation of PRIOR) etc $TABLE ...COM(x+1)=G11 .. I have not used this combination, so this is the untested idea. Leonid -- Leonid Gibiansky, Ph.D. President

Re: [NMusers] permissible band matrix

det(aa) [1] -2945 Leonid -- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web:www.quantpharm.com e-mail: LGibiansky at quantpharm.com tel:(301) 767 5566 Sam Liao wrote: Dear NONMEM users: Can someone please help me to solve this problem

Re: [NMusers] $MIX and $CONTR

be time varying. In the example proposed in the NONMEM help the covariate proposed for use in $MIX is AGE. If AGE is properly recorded in the data set then AGE is guaranteed to be a time varying covariate! Nick Leonid Gibiansky wrote: Nick, I am not sure that the entire idea is correct: subject can

Re: [NMusers] $MIX and $CONTR

in the example above). Nick Leonid Gibiansky wrote: Nick, I think you are reading it incorrectly. I would guess that for a long-term study you may relate probability of response to either baseline age or to the end-of-study age, or to any other age in between, but this value should be one per

Re: [NMusers] Query on model development

Use S2=V/1000 instead of S1=V/1000 Leonid Tausif Ahmed wrote: Dear All, I am new to the field of POP-PK. We are developing a POP-PK model for our in-house drug. The conc. are in ng/mL and dose is in mg. The drug is administered *orally* and follows *1-compartment* model. It has a short

Re: [NMusers] tumor growth model

In Nonmem V (and VI as well), you can put a unit dose to compartment 1, and then estimate bioavailability F1 F1=THETA(...)*EXP(ETA(...)) In Nonmem VI, you can directly supply initial conditions to the compartmental amounts via parameter A_0(1), e.g., A_0(1)=THETA(...)*EXP(ETA(...)) (see

Re: [NMusers] How does TIME work for multiple doses in NONMEM?

TIME is not reset, it is counted from the first dose in this example. To describe the model you need to introduce TAD (time after the most recent dose) into the data set and use it for FLAG reset: IF(TAD.GT.LAG) FLAG=1 Same with occasion, it would be best to introduce variable OCC (occasion, 1

Re: [NMusers] trough time same as dosing time

Should not be a problem for oral administration. If IV, make sure that trough observation records are before the dosing records (time can be the same, but they should be ordered correctly). Leonid Ying HONG wrote: Dear NMusers, A single-dose of drug was given to healthy volunteers and a PK

[NMusers] ETABAR p-value

Dear All, Could anyone help me to interpret ETAbar p value? I have: TOT. NO. OF OBS RECS:1486 TOT. NO. OF INDIVIDUALS: 213 ETABAR: -0.52E-02 -0.27E-01 -0.93E-01 P VAL.: 0.90E+00 0.24E+00 0.81E-04 ETA1 ETA2 ETA3 ETA1 4.08E-01 ETA2 2.26E-01 2.31E-01 ETA3

<    1   2   3